IBI3016 for hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Jan 2026: Trial registered, NCT07352969
  2. 5 Feb 2026: Trial started, NCT07352969

The trials

NCT07352969: A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

State
Under way
Phase
Phase 2
People
352 taking part
Started
5 Feb 2026
Primary completion
27 Mar 2029
Arms
IBI3016 dose 4, IBI3016 dose 1, IBI3016 dose 2, IBI3016 dose 3, IBI3016 dose 5
Results
None posted
  1. 20 Jan 2026: Trial registered
  2. 5 Feb 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.